Determination of atomoxetine and its metabolites in conventional and non-conventional biological matrices by liquid chromatography-tandem mass spectrometry

Journal of Pharmaceutical and Biomedical Analysis

Volumn 60, Issue , 2012, Pages 26-31

  Marchei, Emilia ^a   Papaseit, Esther ^b,c   Garcia Algar, Oscar Q ^b,c   Farrè, Magi ^b,c   Pacifici, Roberta ^a   Pichini, Simona ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^b HOSPITAL DEL MAR   (Spain)

^c UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

Atomoxetine; Oral fluid; Plasma; Sweat; Tandem mass spectrometry

Indexed keywords

4 HYDROXYATOMOXETINE; ACETONITRILE; AMMONIUM ACETATE; ATOMOXETINE; DRUG METABOLITE; DULOXETINE; FORMIC ACID; N DES METHYLATOMOXETINE; TRIFLUOROACETIC ACID; UNCLASSIFIED DRUG; WATER;

ADOLESCENT; ARTICLE; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG URINE LEVEL; ELECTROSPRAY MASS SPECTROMETRY; FEMALE; HUMAN; HUMAN TISSUE; LIQUID CHROMATOGRAPHY TANDEM MASS SPECTROMETRY; MALE; MASS SPECTROMETRY; PRIORITY JOURNAL; SWEAT;

ADOLESCENT; ADRENERGIC UPTAKE INHIBITORS; CHROMATOGRAPHY, LIQUID; FEMALE; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HUMANS; LIMIT OF DETECTION; MALE; PROPYLAMINES; SALIVA; SWEAT; TANDEM MASS SPECTROMETRY;

EID: 83955165252     PISSN: 07317085     EISSN: 1873264X     Source Type: Journal    
DOI: 10.1016/j.jpba.2011.11.009     Document Type: Article

References (31)

1. Cantwell D.P. Attention deficit disorder: a review of the past 10 years. J. Am. Acad. Child Adolesc. Psychiatry 1996, 35:978-987.
2. Dulcan M. Practice parameters for the assessment and treatment of children, adolescents, and adults with attention-deficit/hyperactivity disorder, American Academy of Child and Adolescent Psychiatry. J. Am. Acad. Child Adolesc. Psychiatry 1997, 36:85S-121S.
3. Swanson J.M., Sergeant J.A., Taylor E., Sonuga-Barke E.J., Jensen P.S., Cantwell D.P. Attention-deficit hyperactivity disorder and hyperkinetic disorder. Lancet 1998, 351:429-433.
4. Faraone S.V., Sergeant J., Gillberg C., Biederman J. The worldwide prevalence of ADHD: is it an American condition?. World Psychiatry 2003, 2:104-113.
5. Polanczyk G., de Lima M.S., Horta B.L., Biederman J., Rohde L.A. The worldwide prevalence of ADHD: a systematic review and metaregression analysis. Am. J. Psychiatry 2007, 164:942-948.
6. Klein R.G., Mannuzza S. Long-term outcome of hyperactive children: a review. J. Am. Acad. Child Adolesc. Psychiatry 1991, 30:383-387.
7. Dulcan M.K., Benson R.S. AACAP Official Action. Summary of the practice parameters for the assessment and treatment of children, adolescents, and adults with ADHD. J. Am. Acad. Child Adolesc. Psychiatry 1997, 36:1311-1317.
8. Goldman L.S., Genel M., Bezman R.J., Slanetz P.J. Diagnosis and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Council on Scientific Affairs, American Medical Association. JAMA 1998, 279:1100-1107.
9. Elia J., Ambrosini P.J., Rapoport J.L. Treatment of attention-deficit-hyperactivity disorder. N. Engl. J. Med. 1999, 340:780-788.
10. Baughman F.A. Treatment of attention-deficit/hyperactivity disorder. JAMA 1999, 281:1490.
11. Michelson D., Faries D., Wernicke J., Kelsey D., Kendrick K., Sallee F.R., Spencer T. Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study. Pediatrics 2001, 108:E83.
12. Witcher J.W., Long A., Smith B., Sauer J.M., Heilgenstein J., Wilens T., Spencer T., Biederman J. Atomoxetine pharmacokinetics in children and adolescents with attention deficit hyperactivity disorder. J. Child Adolesc. Psychopharmacol. 2003, 13:53-63.
13. Wong D.T., Threlkeld P.G., Best K.L., Bymaster F.P. A new inhibitor of norepinephrine uptake devoid of affinity for receptors in rat brain. J. Pharmacol. Exp. Ther. 1982, 222:61-65.
14. Gehlert D.R., Gackenheimer S.L., Robertson D.W. Localization of rat brain binding sites for [3H]tomoxetine, an enantiomerically pure ligand for norepinephrine reuptake sites. Neurosci. Lett. 1993, 157:203-206.
15. Ring B.J., Gillespie J.S., Eckstein J.A., Wrighton S.A. Identification of the human cytochromes P450 responsible for atomoxetine metabolism. Drug Metab. Dispos. 2002, 30:319-323.
16. Sauer J.M., Ponsler G.D., Mattiuz E.L., Long A.J., Witcher J.W., Thomasson H.R., Desante K.A. Disposition and metabolic fate of atomoxetine hydrochloride: the role of CYP2D6 in human disposition and metabolism. Drug Metab. Dispos. 2003, 31:98-107.
17. Farid N.A., Bergstrom R.F., Ziege E.A., Parli C.J., Lemberger L. Single-dose and steady-state pharmacokinetics of tomoxetine in normal subjects. J. Clin. Pharmacol. 1985, 25:296-301.
18. Michelson D., Read H.A., Ruff D.D., Witcher J., Zhang S., McCracken J. CYP2D6 and clinical response to atomoxetine in children and adolescents with ADHD. J. Am. Acad. Child Adolesc. Psychiatry 2007, 46:242-251.
19. Mullen J.H., Shugert R.L., Ponsler G.D., Li Q., Sundaram B., Coales H.L., Yakupkovic J.E., Lelacheur R.M., Wheeler W.J., Belas F.J., Sauer J.M. Simultaneous quantification of atomoxetine as well as its primary oxidative and O-glucuronide metabolites in human plasma and urine using liquid chromatography tandem mass spectrometry (LC/MS/MS). J. Pharm. Biomed. Anal. 2005, 38:720-733.
20. Choong E., Rudaz S., Kottelat A., Guillarme D., Veuthey J.L., Eap C.B. Therapeutic drug monitoring of seven psychotropic drugs and four metabolites in human plasma by HPLC-MS. J. Pharm. Biomed. Anal. 2009, 50:1000-1008.
21. Zhu H.J., Wang J.S., Donovan J.L., DeVane C.L., Gibson B.B., Markowitz J.S. Sensitive quantification of atomoxetine in human plasma by HPLC with fluorescence detection using 4-(4,5-diphenyl-1H-imidazole-2-yl) benzoyl chloride derivatization. J. Chromatogr. B: Analyt. Technol. Biomed. Life Sci. 2007, 846:351-354.
22. Patel C., Patel M., Rani S., Nivsarkar M., Padh H. A new high performance liquid chromatographic method for quantification of atomoxetine in human plasma and its application for pharmacokinetic study. J. Chromatogr. B: Analyt. Technol. Biomed. Life Sci. 2007, 850:356-360.
23. Guo W., Li W., Guo G., Zhang J., Zhou B.B., Zhai Y., Wang C. Determination of atomoxetine in human plasma by a high performance liquid chromatographic method with ultraviolet detection using liquid-liquid extraction. J. Chromatogr. B: Analyt. Technol. Biomed. Life Sci. B 2007, 854:128-134.
24. E. Papaseit, E. Marchei, C. Mortali, G. Aznar, O. Garcia-Algar, M. Farrè, R. Pacifici, S. Pichini, Development and validation of a liquid chromatography-tandem mass spectrometry assay for hair analysis of atomoxetine and its metabolites: application in clinical practice, Forensic Sci. Int. (2011), Oct 22 [Epub ahead of print].
25. Guidance for Industry, Bioanalytical of Health and Human Services, Food and Drug Administration, May 2001. Available from: http://www.fda.gov/cder/guidance/4252fnl.htm.
26. ICH-Topic Q2B: Validation of Analytical Procedures: Methodology, International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use, Geneva, 1996.
27. Marchei E., Escuder D., Pallas C.R., Garcia-Algar O., Gómez A., Friguls B., Pellegrini M., Pichini S. Simultaneous analysis of frequently used licit and illicit psychoactive drugs in breast milk by liquid chromatography tandem mass spectrometry. J. Pharm. Biomed. Anal. 2011, 55:309-316.
28. Navarro M., Pichini S., Farré M., Ortuno J., Roset P.N., Segura J., de la Torre R. Usefulness of saliva for measurement of 3,4-methylenedioxymethamphetamine and its metabolites: correlation with plasma drug concentrations and effect of salivary pH. Clin. Chem. 2001, 47:1788-1795.
29. Marchei E., Farré M., Pardo R., Garcia-Algar O., Pellegrini M., Pacifici R., Pichini S. Correlation between methylphenidate and ritalinic acid concentrations in oral fluid and plasma. Clin. Chem. 2010, 56:585-592.
30. Sauer J.M., Ring B.J., Witcher J.W. Clinical pharmacokinetics of atomoxetine. Clin. Pharmacokinet. 2005, 44:571-590.
31. Pichini S., Navarro M., Pacifici R., Zuccaro P., Ortuno J., Farré M., Roset P.N., Segura J., de la Torre R. Usefulness of sweat testing for the detection of MDMA after a single-dose administration. J. Anal. Toxicol. 2003, 27:294-303.